Homegrown China Oral Antiviral Shows Early Promise
Shortens Viral Shedding
Executive Summary
Junshi’s oral antiviral shows signs of effectiveness in treating patients with mild COVID-19 symptoms but more data are needed, caution researchers.
You may also be interested in...
Curious Case Of LHQW: Behind The TCM Central To China’s COVID Zero Policies
The role of a traditional Chinese medicine provided to the general public in China to fend off COVID-19 is controversial given limited evidence and even misleading, some say.
China’s Home-Grown Oral COVID Antiviral Eyes Wider Population
Simcere is weighing options for SIM0417 in a Phase I trial in China as the first major domestically-developed potential rival to Pfizer’s oral COVID-19 antiviral Paxlovid. The study is likely to include wider patient groups ranging from those without symptoms to severe patients.
Domestic Firms Play Oral Antiviral Catchup As China Approves Paxlovid
With home-grown 3CL protease inhibitors for COVID-19 still shrouded in uncertainty, some companies in China are now turning to oral RNA polymerase inhibitors as a nearer term option for both mild-to-moderate and severe patients.